BioSpace News Archive

Eiger BioPharmaceuticals , Inc. ( Nasdaq : EIGR ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus ( HDV ) and other serious diseases, today announced the appointment of Lisa Kelly-Croswell to its Board of Directors.

Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting taking place July 25-29 in Toronto.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the first patient has been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating the administration of THIO, in sequence with cemiplimab, in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference.

Alzamend Neuro, Inc. today announced that it has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (the “FDA”).

Acer Therapeutics Inc. today announced the resubmission of Acer’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders.

Broncus Medical (02216.HK) has completed surgeries on the first group of patients using its InterVapor®(including InterVapor Generator and InterVapor Catheter, the “InterVapor®"), after it was approved for marketing in China.

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock.

Werfen today announced the 510(k) clearance of the ROTEM sigma Thromboelastometry System by the US Food and Drug Administration (FDA).